Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | BDKRB1 | P46663 | 12/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | STAT5B | P51692 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937873 | 0.92 | PARP1 (0.41) | PARP1BDKRB1TSHRUSP2SMN1; SMN2 | |
| SCHEMBL11947883 | 0.84 | PARP1 (0.43) | PARP1BDKRB1TSHRPPARGFABP4 | |
| SCHEMBL939680 | 0.80 | CYP2D6 (0.46) | BDKRB1TSHRUSP2SMN1; SMN2 | |
| SCHEMBL939382 | 0.77 | SMN1; SMN2 (0.38) | BDKRB1SMN1; SMN2STAT5B | |
| SCHEMBL11947880 | 0.77 | PARP1 (0.42) | PARP1BDKRB1TSHR | |
| SCHEMBL941264 | 0.75 | KDM4C (0.41) | BDKRB1TSHRUSP2SMN1; SMN2STAT5B | |
| SCHEMBL937871 | 0.74 | PARP1 (0.40) | PARP1TSHRSTING1PPARG | |
| SCHEMBL938282 | 0.73 | DHODH (0.44) | BDKRB1SMN1; SMN2FABP4 | |
| SCHEMBL11947881 | 0.71 | PARP1 (0.44) | PARP1TSHRSMN1; SMN2 | |
| SCHEMBL940269 | 0.71 | SMN1; SMN2 (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440542-B1 | Substituted benzimidazoles, benzonthiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | BDKRB1, BDKRB2, BRD1 | PARP1 1156/4885BDKRB1 1/4885TSHR 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.